Trial Profile
A Phase I/II Dose Escalation Study Evaluating Safety and Activity of Autologous CD34+-Enriched Hematopoietic Progenitor Cells Genetically Modified With a Lentiviral Vector Encoding for the Human Interferon-ɑ2 Gene in Multiple Myeloma Patients With Early Relapse After Intensive Front Line Therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Interferon alpha 2 gen e therapy-GenentaScience (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Filgrastim; Lenalidomide; Lenograstim; Melphalan; Plerixafor
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms TEM-MM
- Sponsors Genenta Science
- 27 Jan 2022 Status changed from recruiting to discontinued, reason: failure to recruit patients
- 10 Dec 2019 Trial design assessing Safety and Activity of Human Interferon-a2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 13 Mar 2019 Status changed from planning to recruiting.